New study on the viability of donated livers and its correlation with donor demographics has been conducted by a group of researchers from Harvard Medical School and published in a forthcoming issue of TECHNOLOGY. The results of this study could lead to a reduction in the number of livers that are discarded and have repercussions for development of novel therapeutics and bioengineering for clinical research applications.
In order to lessen the burden on orthotopic liver transplantation, which is currently the only treatment for end stage liver disease, many researchers and scientists are exploring different avenues and developing techniques to address the shortage of livers for transplant. Techniques such as recellularized bioengineered livers and hepatic cell transplantation are exciting but still remain limited on a clinical level. In addition, new pharmaceutical therapies rely on primary hepatocytes to determine the toxicity, metabolism, and drug-drug interactions necessary for US Food and Drug Administration approval. A large source of human hepatocytes is thereby beneficial for continuing this research as well as potentially developing new lines of therapy both clinically and pharmaceutically. The question remains, where do large sources of primary hepatocytes come from?
Donor demographics such as race and gender had significant impacts on viability and yield while demographics such as BMI, age, donor status, cause of death did not. In addition, liver procurement data such as WIT showed that organs with less than 30 mins WIT led to significantly reduced yield, but no impact was found on viability. Cold ischemia time had no impact on yield, but longer CIT did decrease the viability of hepatocytes.
Though the number of livers was small (n=16) and should be taken into consideration, the conclusions drawn could be used as indications to expand liver selection criteria for hepatocyte isolations for many researchers and incorporate livers from donors that would have otherwise been discarded.